Dataset Information


Effect-site concentration of propofol required for LMA-Supreme™ insertion with and without remifentanil: a randomized controlled trial.

ABSTRACT: A new supraglottic device, the LMA-Supreme™, has recently become available for clinical use. Information on anaesthetic and co-adjuvant requirements for insertion of the LMA-Supreme™ is limited. The present study aimed to evaluate the optimal effect-site concentration of propofol in 50 % (EC50) of adults necessary for successful insertion of the LMA-Supreme™ and to examine remifentanil's effect on propofol requirements.Fifty-eight elective patients (aged 18-60 years; ASA (American Society Anaesthesiologists) physical status classification I and II) scheduled for day surgery were randomly assigned to one of two groups: propofol with saline or propofol with remifentanil. Anaesthesia was induced by target-controlled infusion according to predetermined effect-site concentrations of propofol and remifentanil (5 ng.mL(-1)). The EC50 was calculated using Dixon's up-and-down method. Ten minutes following drug administration, LMA-Supreme™ insertion was attempted without the use of muscle relaxant drugs.In the propofol + saline group, the EC50 of propofol required for LMA-Supreme™ insertion was 6.32 ± 0.67 ?g.mL(-1) (95 % CI, 5.69-6.94 ?g.mL(-1)). With the addition of remifentanil at an effect-site concentration of 5 ng.mL(-1), the EC50 of propofol required for LMA-Supreme™ insertion was 2.50 ± 0.80 ?g.mL(-1) (95 % CI, 1.82-3.17 ?g.mL(-1); p < 0.0001).The propofol requirement for smooth insertion of the LMA-Supreme™ was 60 % less when remifentanil (5 ng.mL(-1)) was co-administered.Identified as NCT01974648 at www.clinicaltrials.gov .

SUBMITTER: Zaballos M 

PROVIDER: S-EPMC4595052 | BioStudies | 2015-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3741209 | BioStudies
2017-01-01 | S-EPMC5581452 | BioStudies
2017-01-01 | S-EPMC5584514 | BioStudies
2020-01-01 | S-EPMC6945475 | BioStudies
2020-01-01 | S-EPMC7664089 | BioStudies
2019-01-01 | S-EPMC6610917 | BioStudies
2017-01-01 | S-EPMC5348200 | BioStudies
2018-01-01 | S-EPMC6072370 | BioStudies
2018-01-01 | S-EPMC6011323 | BioStudies
1000-01-01 | S-EPMC3790608 | BioStudies